Used in pharmaceutical synthesis as an intermediate for developing bioactive molecules, particularly in the preparation of kinase inhibitors and other therapeutic agents targeting inflammatory and oncological pathways. Its structure supports selective binding and enhanced metabolic stability, making it valuable in medicinal chemistry for optimizing drug candidates. Commonly employed in late-stage functionalization due to the presence of the methylsulfonyloxy (mesylate) leaving group, enabling carbon-carbon and carbon-heteroatom bond formation under mild coupling conditions. Also utilized in the development of protease inhibitors and receptor modulators where piperidine and benzimidazole moieties contribute to target affinity and pharmacokinetic properties.